Persisent ocular hypertension following intravitreal ranibizumab

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 7, 2008, Pages 955-958

  Bakri, Sophie J ^a   McCannel, Colin A ^a   Edwards, Albert O ^a   Moshfeghi, Darius M ^b  

^a MAYO CLINIC   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Anti VEGF; Glaucoma; Intraocular pressure; Intravitreal; Lucentis; Ocularhy pertension; Pressure increase; Ranibizumab

Indexed keywords

ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; BEVACIZUMAB; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; METHAZOLAMIDE; PEGAPTANIB; RANIBIZUMAB; TIMOLOL MALEATE; TRIAMCINOLONE; VERTEPORFIN;

AGED; ARTICLE; CASE REPORT; CAUCASIAN; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GLAUCOMA; GONIOSCOPY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRESCRIPTION; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; VISUAL SYSTEM EXAMINATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIHYPERTENSIVE AGENTS; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MACULAR DEGENERATION; MALE; OCULAR HYPERTENSION; TONOMETRY, OCULAR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 44649111100     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-008-0819-2     Document Type: Article

References (9)

1. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J (2007) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye Aug 10; [Epub ahead of print]
2. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355(14):1419-1431
3. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355(14):1432-1444
4. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805-2816
5. D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B, VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group (2006) Pegaptanib sodium for neovascular age-related macular degeneration: Two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113(6):992-1001, e6
6. Kubota T, Okabe H, Hisatomi T, Yamakiri K, Sakamoto T, Tawara A (2006) Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 15(2):117-119
7. Shinzato M, Yamashiro Y, Miyara N, Iwamatsu A, Takeuchi K, Umikawa M, Bayarjargal M, Kariya K, Sawaguchi S (2007) Proteomic analysis of the trabecular meshwork of rats in a steroid-induced ocular hypertension model: Downregulation of type I collagen C-propeptides. Ophthalmic Res 39(6):330-337
8. Leung YF, Tam PO, Lee WS, Lam DS, Yam HF, Fan BJ, Tham CC, Chua JK, Pang CP (2003) The dual role of dexamethasone on anti-inflammation and outflow resistance demonstrated in cultured human trabecular meshwork cells. Mol Vis 9:425-439
9. Rozsa FW, Reed DM, Scott KM, Pawar H, Moroi SE, Kijek TG, Krafchak CM, Othman MI, Vollrath D, Elner VM, Richards JE (2006) Gene expression profile of human trabecular meshwork cells in response to long-term dexamethasone exposure. Mol Vis 12:125-141